Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLLS Cellectis	$2.77 -1.8%	$2.07	$1.10 ▼ $3.24	$153.96M	3.03	227,656 shs	48,405 shs
TERN Terns Pharmaceuticals	$6.76 +7.3%	$5.16	$1.87 ▼ $11.40	$591.57M	-0.05	1.17 million shs	1.12 million shs
TSHA Taysha Gene Therapies	$2.87	$2.61	$1.05 ▼ $3.31	$616.07M	0.98	2.88 million shs	1.69 million shs
VIR Vir Biotechnology	$4.38 +0.5%	$5.16	$4.16 ▼ $14.45	$608.47M	1.18	1.56 million shs	829,625 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLLS Cellectis	-5.37%	+1.08%	+54.10%	+81.35%	+22.61%
TERN Terns Pharmaceuticals	-3.82%	-2.93%	+11.70%	+114.29%	-16.11%
TSHA Taysha Gene Therapies	+1.06%	-5.28%	+13.44%	+0.70%	+25.33%
VIR Vir Biotechnology	0.00%	-4.60%	-21.01%	-5.42%	-50.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLLS Cellectis	3.3286 of 5 stars	3.5	5.0	0.0	3.0	2.5	0.0
TERN Terns Pharmaceuticals	3.4933 of 5 stars	3.3	1.0	4.1	0.6	3.3	0.0
TSHA Taysha Gene Therapies	3.384 of 5 stars	4.5	2.0	0.0	2.4	3.3	0.0
VIR Vir Biotechnology	3.3613 of 5 stars	3.4	2.0	0.0	3.0	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLLS Cellectis	3.00	Buy	$4.00	44.40% Upside
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	131.14% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.29	188.70% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	590.64% Upside

Current Analyst Ratings Breakdown

Latest CLLS, TSHA, VIR, and TERN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	TSHA Taysha Gene Therapies	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.50 ➝ $8.00
8/12/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	TSHA Taysha Gene Therapies	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
7/1/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLLS Cellectis	$49.22M	3.13	N/A	N/A	$1.75 per share	1.58
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$3.49 per share	N/A
TSHA Taysha Gene Therapies	$8.33M	73.96	N/A	N/A	$1.16 per share	2.47
VIR Vir Biotechnology	$74.21M	8.20	N/A	N/A	$6.82 per share	0.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLLS Cellectis	-$36.76M	-$0.82	N/A	N/A	N/A	-100.69%	-68.05%	-21.53%	11/3/2025 (Estimated)
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	N/A	N/A	N/A	N/A	-27.35%	-26.18%	N/A
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,144.97%	-78.44%	-44.82%	N/A
VIR Vir Biotechnology	-$521.96M	-$4.00	N/A	N/A	N/A	-2,895.94%	-50.22%	-40.78%	10/30/2025 (Estimated)

Latest CLLS, TSHA, VIR, and TERN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	TSHA Taysha Gene Therapies	-$0.07	-$0.09	-$0.02	-$0.09	$1.61 million	$1.99 million
8/6/2025	Q2 2025	VIR Vir Biotechnology	-$0.72	-$0.80	-$0.08	-$0.80	$2.38 million	$1.21 million
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A
8/4/2025	Q2 2025	CLLS Cellectis	-$0.15	-$0.24	-$0.09	-$0.24	$10.07 million	$18.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLLS Cellectis	0.58	1.38	1.38
TERN Terns Pharmaceuticals	N/A	24.70	24.70
TSHA Taysha Gene Therapies	0.17	12.48	12.48
VIR Vir Biotechnology	N/A	7.01	7.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLLS Cellectis	63.90%
TERN Terns Pharmaceuticals	98.26%
TSHA Taysha Gene Therapies	77.70%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
CLLS Cellectis	16.41%
TERN Terns Pharmaceuticals	1.50%
TSHA Taysha Gene Therapies	3.78%
VIR Vir Biotechnology	16.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable
VIR Vir Biotechnology	580	138.92 million	116.69 million	Optionable

CLLS, TSHA, VIR, and TERN Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Tejara Capital Ltd

August 17, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for VIR Earnings

August 12, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Outlook for VIR Earnings

August 12, 2025 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month Low - Here's Why

August 10, 2025 | marketbeat.com

Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)

August 9, 2025 | theglobeandmail.com

Vir Biotechnology (NASDAQ:VIR) Trading Down 11.1% Following Weak Earnings

August 8, 2025 | marketbeat.com

Vir Biotechnology Reports Q2 2025 Financial Results

August 7, 2025 | msn.com

Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum

August 7, 2025 | msn.com

Vir (VIR) Q2 Revenue Drops 61%

August 7, 2025 | fool.com

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 6, 2025 | businesswire.com

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

August 6, 2025 | businesswire.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells $109,780.00 in Stock

August 5, 2025 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from Brokerages

August 1, 2025 | marketbeat.com

Vir Biotechnology Pivots to Cancer, Infectious Disease after Commercial and Clinical Setbacks

July 31, 2025 | genengnews.comG

Vir Biotechnology (VIR) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

July 31, 2025 | businesswire.com

Allianz Asset Management GmbH Has $2 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Has $1.12 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

July 31, 2025 | marketbeat.com

Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

July 30, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLLS, TSHA, VIR, and TERN Company Descriptions

Cellectis NASDAQ:CLLS

$2.76 -0.06 (-2.13%)

As of 04:00 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Terns Pharmaceuticals NASDAQ:TERN

$6.76 +0.46 (+7.30%)

Closing price 04:00 PM Eastern

Extended Trading

$6.77 +0.01 (+0.15%)

As of 04:40 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Taysha Gene Therapies NASDAQ:TSHA

$2.87 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.88 +0.00 (+0.17%)

As of 04:10 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Vir Biotechnology NASDAQ:VIR

$4.38 +0.02 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$4.38 0.00 (-0.11%)

As of 04:42 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time